MedTrace Logo

Platelet Rich Plasma for Uterine Scar

NCT05224726 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2025-08-26

No results posted yet for this study

Summary

When vessel wall injury occurs, platelets become activated, releasing more than 30 bioactive proteins, many of which have a fundamental role in hemostasis, inflammation and ultimate wound healing. Platelet-rich plasma (PRP), a modification of fibrin glue made from autologous blood, is being used to deliver growth factors in high concentration to sites requiring wound healing. PRP is obtained from a sample of patients' blood drawn at the time of treatment. As the rate of cesarean deliveries has been rising, long-term adverse sequelae due to uterine scar defects have been increasing. PRP might be a simple preventive treatment that potentially can reduce morbidity following cesarean deliveries.

Conditions

  • Cesarean Section Complications
  • Uterine Bleeding
  • Pelvic Pain
  • Menstrual Irregularity

Interventions

OTHER

Platelet Rich Plasma

Injection of 5cc of PRP preparation at the myometrium around the uterine incision after it has been sutured.

OTHER

Placebo

Injection of 5cc of 0.9% Normal Saline at the myometrium around the uterine incision after it has been sutured.

Sponsors & Collaborators

  • Sheba Medical Center

    collaborator OTHER_GOV

  • The University of Texas Health Science Center, Houston

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
52 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-07-19
Primary Completion
2028-07-01
Completion
2028-07-01

Countries

  • Israel

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05224726 on ClinicalTrials.gov